Drug Delivery Business

Insulet resumes next-gen Omnipod pivotal study following software issues

By

InsuletInsulet (NSDQ:PODD) today said it has resumed its pivotal study of its next-generation Omnipod Insulin Management System after pausing the study in March due to a software anomaly.

The company paused the study about halfway through completion to correct an issue that could result in the system using an incorrect glucose value that had the potential to impact insulin delivery, according to the company. No adverse events it had been reported due to the software issue.

Get the full story on our sister site, MassDevice.

IN CASE YOU MISSED IT

About Danielle Kirsh

Danielle Kirsh is an award-winning journalist and senior editor for Medical Design & Outsourcing, MassDevice, and Medical Tubing + Extrusion, and the founder of Women in Medtech and lead editor for Big 100. She received her bachelor's degree in broadcast journalism and mass communication from Norfolk State University and is pursuing her master's in global strategic communications at the University of Florida. You can connect with her on Twitter and LinkedIn, or email her at [email protected].